United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Hemab Therapeutics raises $135m for prophylactic treatments for bleeding and thrombotic disorders Hemab Therapeutics, a clinical-stage biotechnology company, has raised $135 million in a Series B financing round for advancing… byRaghuram KadariFebruary 22, 2023